Latest Cancer immunotherapy Stories

A clinical trial of an experimental new breast cancer treatment found that it extended the life expectancy of patients without the symptoms of the disease worsening, various media outlets reported on Sunday. The drug, TDM-1, is manufactured by Roche, and according to Naomi Kresge and Robert Langreth of Bloomberg, it works by carrying chemotherapy directly into cancer cells while successfully avoiding healthy ones, resulting in fewer side effects than conventional treatments. According...

• Clinical Activity of Anti-PD-1 Published in New England Journal of Medicine (NEJM) and Presented at 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) • Phase 1 Data on Second Investigational Immunotherapy (Anti-PD-L1) Also Published in NEJM and Presented at ASCO Milwaukee, WI (PRWEB) June 02, 2012 SITC leaders publish landmark studies of new cancer immunotherapeutics Clinical activity of two cancer immunotherapeutic agents, anti-PD-1 and anti-PD-L1 were...

TAU researcher develops new antibodies to target and destroy cancer cells Because cancer cells grow very quickly, chemotherapy is designed to target cells whose numbers grow rapidly. But this treatment comes with a heavy price — many healthy cells essential for body functions are also targeted and killed by the toxin. This dangerous side-effect has prompted researchers to seek better and more selective ways to kill cancer cells inside the body. Prof. Daniel Wreschner of Tel Aviv...

WORCESTER, Mass. and TORONTO, May 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) is pleased to announce today that new members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc. for the company's AE37 breast cancer vaccine. The following distinguished investigators join Dr. Gabriel N. Hortobagyi, MD, FACP (University of Texas MD Anderson Cancer Center), Dr. Kathy D. Miller, MD (Indiana University School...

Rather than stimulating immune cells to more effectively battle cancerous tumors, treatment with the protein interleukin-12 (IL-12) has the opposite effect, driving these intracellular fighters to exhaustion, a Mayo Clinic study has found. The findings appear in the Journal of Clinical Investigation. The study helps explain the negative results of clinical trials testing the treatment's ability to ramp up the body's natural immune response to destroy cancer cells. The study also demonstrates...

WORCESTER, Mass. and TORONTO, May 9, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that a Scientific Advisory Board (SAB) has been established for its wholly-owned oncology immuno-therapeutics subsidiary, Antigen Express, Inc. The function of the SAB is to provide advice and assistance to Antigen Express in respect of the clinical and regulatory programs for the Company's immuno-therapeutic cancer vaccines. The initial focus of the...

WORCESTER, Mass. and TORONTO, April 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the American Association for Cancer Research (AACR) chose to spotlight a presentation on data from the ongoing clinical trial of AE37, an immunotherapeutic vaccine to prevent relapse in patients who have had breast cancer being developed by Antigen Express, in a press conference. The annual AACR meeting is one of the largest national cancer conferences...

Fox Chase scientists suggest that the findings could also serve as a new target for treatment Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments. The findings will be reported at the AACR Annual Meeting 2012 on Sunday, April 1. The researchers found that patients whose tumors had higher levels of the protein...

Human tumors transplanted into laboratory mice disappeared or shrank when scientists treated the animals with a single antibody, according to a new study from the Stanford University School of Medicine. The antibody works by masking a protein flag on cancer cells that protects them from macrophages and other cells in the immune system. The scientists achieved the findings with human breast, ovarian, colon, bladder, brain, liver and prostate cancer samples. It is the first antibody...

RESEARCH TRIANGLE PARK, N.C., March 20, 2012 /PRNewswire/ -- AlphaVax, Inc. ("AVX") is pleased to report that it has been selected as a corporate nominee for the 2012 Vaccine Industry Excellence Award as the Best Early-Stage Vaccine Biotech Company. The award will be announced during the World Vaccine Congress meeting in Washington, DC in April. AVX is pleased to be both included in the list of finalists as deemed by the panel of judges as well as being recognized as a leader in...